跳至主要内容
临床试验/CTRI/2024/07/071339
CTRI/2024/07/071339招募中3 期

A Randomized, four arm, double blind, placebo controlled Clinical Trial to evaluate the efficacy and safety of SG product in the improvement of Muscle strength and endurance in male subjects. - NI

KAPIVA0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • •1.Male volunteers between the age group of 25-45 years.
  • •2.Subjects who are familiar with weight training and had atleast 4 months of experience in the gym (defined as 4 times per week for minimum of 3 to 4 hours per week).
  • •3.Subjects who are willing and able to understand and follow the protocol and provide informed consent.
  • •4.Agree not to use any medication (prescription and over the counter), including vitamins and minerals, and any alternative medications during the course of this study.
  • •5.Subjects whose blood chemistries are within a normal range or not
  • •considered clinically significant if outside the normal range

排除标准

  • •1.Concomitant severe decompensated systemic disease (cardiovascular, renal, hepatic, endocrine, hematological, neurological, immunological)
  • •2.Patients with pre-existing severe systemic disease necessitating long-term medication.
  • •3.Subjects suffering from any serious medical or surgical illness.
  • •4.History of cancer, including solid tumors, hematologic malignancies and carcinoma in situ.
  • •5.Any neurological (congenital or acquired), musculoskeletal, joint health conditions, psychological, vascular or systemic disorder which could affect any of the efficacy assessments.
  • •6.Significant abnormal findings as determined by baseline history, physical examination, vital signs (blood pressure, pulse rate, respiration rate), ECG hematology, serum chemistry.
  • •7.More than 4 short courses of oral corticosteroids within the year preceding the screening visit, or any oral corticosteroids in the preceding 4 weeks.
  • •8.Use of Astemizole, Nedocromil, Cromolyn, long acting ß agonists, Ketotifen, Theophylline or testosterone within 4 weeks before.
  • •9.Participation in the current or previous clinical trial with any
  • •approved investigational products during the past 1 month.

研究者

发起方
KAPIVA

相似试验

进行中(未招募)
不适用
A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course. - Atacicept frequent MRI study in RMSRelapsing multiple sclerosisMedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosis
EUCTR2007-003936-50-CZMerck Serono SA - Geneva, an affiliate of Merck KGaA, Darmstadt, Germany255
进行中(未招募)
不适用
A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course. - Atacicept frequent MRI study in RMSMedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisRelapsing multiple sclerosis
EUCTR2007-003936-50-NLMerck Serono International S.A.332
进行中(未招募)
不适用
A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course. - Atacicept frequent MRI study in RMSRelapsing multiple sclerosisMedDRA version: 13.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disorders
EUCTR2007-003936-50-GBMerck Serono S.A. - Geneva255
进行中(未招募)
不适用
A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course. - Atacicept frequent MRI study in RMSRelapsing multiple sclerosisMedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosis
EUCTR2007-003936-50-SEMerck Serono Geneva- an affiliate of Merck KGaA, Darmstadt Germany255
进行中(未招募)
1 期
A four-arm randomised, double-blind, placebo-controlled, multicentre Phase II study to evaluate the safety, tolerability and efficacy as assessed by frequent MRI measures of three doses of atacicept monotherapy in subjects with relapsing multiple sclerosis (RMS) over a 36 weeks treatment course. - Atacicept frequent MRI study in RMSRelapsing multiple sclerosisMedDRA version: 9.1Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosis
EUCTR2007-003936-50-FRMerck Serono International S.A.332